Fulcrum Therapeutics (FULC) Price & Analysis

Compare

504 Followers

FULC Stock Chart & Stats

$11.32

-$0.39(-7.98%)

At close: Jan 08 4:00 PM EST

$11.32

-$0.39(-7.98%)

Day’s Range― - ―

52-Week Range$2.32 - $12.19

Previous CloseN/A

Volume345.04K

Average Volume (3M)764.07K

Market Cap

$635.35M

Enterprise Value$382.26M

Total Cash (Recent Filing)$200.65M

Total Debt (Recent Filing)$7.01M

Price to Earnings (P/E)―

Beta1.10

Next Earnings

Feb 26, 2026

EPS Estimate

-0.32

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.31

Shares Outstanding54,118,440

10 Day Avg. Volume991,518

30 Day Avg. Volume764,071

Financial Highlights & Ratios

PEG Ratio0.33

Price to Book (P/B)1.20

Price to Sales (P/S)3.64

P/FCF Ratio-116.72

Enterprise Value/Market Cap0.60

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-571.39

Enterprise Value/Ebitda-5.28

Forecast

1Y Price Target

$14.50

Price Target Upside28.09% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering9

EPS Forecast (FY)-1.17

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Trial ResultsPociredir continues to show encouraging SCPC trends, with nearly half of patients in the 12 mg cohort experiencing zero SCPCs during treatment.

Efficacy ComparisonPociredir demonstrates stronger efficacy compared to mitapivat in hemoglobin endpoints, both in responder rate and mean change in hemoglobin concentration.

Market Share PotentialPociredir's differentiated mechanism and translational consistency have led to an increased projected penetration slope, indicating potential for greater market share.

Bears Say

Fulcrum Therapeutics News

Fulcrum Therapeutics initiated with a Buy at Truist

Truist initiated coverage of Fulcrum Therapeutics (FULC) with a Buy rating and $14 price target Fulcrum Therapeutics has...

6d ago

FULC

Fulcrum’s pociredir shows promising early efficacy vs. mitapivat, says Leerink

Leerink tells investors in a research note that Phase 3 RISE UP results for Agios’ (AGIO) mitapivat in...

10d ago

AGIO

FULC

Oppenheimer not surprised by Agios data, continues to favor Fulcrum approach

Oppenheimer analyst Matthew Biegler notes that Fulcrum Therapeutics’ (FULC) shares are rallying this morning in the wake of...

10d ago

AGIO

FULC

Caterpillar upgraded, Elf Beauty downgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

24d ago

CAT

Fulcrum Therapeutics resumed with a Buy at Stifel

Stifel resumed coverage of Fulcrum Therapeutics (FULC) with a Buy rating and $20 price target Recent 12mg data...

24d ago

FULC

Buy Rating for Fulcrum Therapeutics Driven by Promising PIONEER Study Results and Market Potential of Pociredir

H.C. Wainwright analyst Andrew Fein has reiterated their bullish stance on FULC stock, giving a Buy rating on...

6d ago

FULC

Fulcrum Therapeutics: Promising Sickle Cell Treatment with Pociredir Outshines Competitors

Analyst Joseph Schwartz of Leerink Partners reiterated a Buy rating on Fulcrum Therapeutics, retaining the price target of...

10d ago

FULC

Fulcrum Therapeutics’ Earnings Call Highlights Progress and Potential

Fulcrum Therapeutics (($FULC)) has held its Q3 earnings call. Read on for the main highlights of the call....

1M ago

FULC

Fulcrum Therapeutics price target raised to $16 from $12.50 at Piper Sandler

Piper Sandler raised the firm’s price target on Fulcrum Therapeutics (FULC) to $16 from $12.50 and keeps an...

1M ago

FULC

Fulcrum Therapeutics Reports Q3 2025 Progress and Financials

Fulcrum Therapeutics ( ($FULC) ) has released its Q3 earnings. Here is a breakdown of the information Fulcrum...

1M ago

FULC

Fulcrum Therapeutics reports Q3 EPS (31c), consensus (29c)

“We are extremely pleased with the compelling data from the 12 mg dose cohort of the PIONEER trial,...

1M ago

FULC

Promising Preclinical Data and Strategic Expansion Drive Buy Rating for Fulcrum Therapeutics

Analyst Andrew Fein of H.C. Wainwright reiterated a Buy rating on Fulcrum Therapeutics, retaining the price target of...

1M ago

FULC

Fulcrum data shows clear dose response with pociredir, says Cantor Fitzgerald

Fulctrum Therapeutics has a new corporate deck on their website that features important details since the readout of...

3M ago

FULC

Fulcrum Therapeutics Highlights Progress in Sickle Cell Treatment

An update from Fulcrum Therapeutics ( ($FULC) ) is now available. On August 28, 2025, Fulcrum Therapeutics released...

3M ago

FULC

FULC FAQ

What was Fulcrum Therapeutics’s price range in the past 12 months?

Fulcrum Therapeutics lowest stock price was $2.31 and its highest was $12.19 in the past 12 months.

What is Fulcrum Therapeutics’s market cap?

Fulcrum Therapeutics’s market cap is $635.35M.

When is Fulcrum Therapeutics’s upcoming earnings report date?

Fulcrum Therapeutics’s upcoming earnings report date is Feb 26, 2026 which is in 88 days.

How were Fulcrum Therapeutics’s earnings last quarter?

Fulcrum Therapeutics released its earnings results on Oct 29, 2025. The company reported -$0.31 earnings per share for the quarter, missing the consensus estimate of -$0.294 by -$0.016.

Is Fulcrum Therapeutics overvalued?

According to Wall Street analysts Fulcrum Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Fulcrum Therapeutics pay dividends?

Fulcrum Therapeutics does not currently pay dividends.

What is Fulcrum Therapeutics’s EPS estimate?

Fulcrum Therapeutics’s EPS estimate is -0.32.

How many shares outstanding does Fulcrum Therapeutics have?

Fulcrum Therapeutics has 54,118,440 shares outstanding.

What happened to Fulcrum Therapeutics’s price movement after its last earnings report?

Fulcrum Therapeutics reported an EPS of -$0.31 in its last earnings report, missing expectations of -$0.294. Following the earnings report the stock price went down -6.4%.

Which hedge fund is a major shareholder of Fulcrum Therapeutics?

Currently, no hedge funds are holding shares in FULC

Fulcrum Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-31.21%

Trailing 12-Months

Asset Growth

-22.99%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Fulcrum Therapeutics

Fulcrum Therapeutics (FULC) is a biotechnology company focused on developing innovative therapies for genetically defined rare diseases. The company utilizes its proprietary drug development platform to identify and advance novel treatments, particularly in the areas of neuromuscular diseases and other conditions caused by genetic mutations. Fulcrum's core products include its lead investigational therapies, aimed at addressing the underlying causes of these diseases and improving patient outcomes.

Fulcrum Therapeutics (FULC) Earnings & Revenues

Historic Earnings Reports

FULC Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call highlighted significant progress in the clinical development of pociredir for sickle cell disease, with promising trial results and a strong financial position. Despite a decrease in cash reserves and continued net losses, the company's achievements and future plans position it well for further advancements.View all FULC earnings summaries

FULC Stock 12 Month Forecast

Average Price Target

$14.50

▲(28.09% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","21":"$21","6.75":"$6.75","11.5":"$11.5","16.25":"$16.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$14.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$6.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,6.75,11.5,16.25,21],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.75,9.615384615384615,10.48076923076923,11.346153846153847,12.211538461538462,13.076923076923077,13.942307692307693,14.807692307692308,15.673076923076923,16.53846153846154,17.403846153846153,18.26923076923077,19.134615384615387,{"y":20,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.75,9.192307692307692,9.634615384615385,10.076923076923077,10.51923076923077,10.961538461538462,11.403846153846153,11.846153846153847,12.288461538461538,12.73076923076923,13.173076923076923,13.615384615384615,14.057692307692307,{"y":14.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.75,8.538461538461538,8.326923076923077,8.115384615384615,7.903846153846154,7.6923076923076925,7.480769230769231,7.269230769230769,7.0576923076923075,6.846153846153847,6.634615384615385,6.423076923076923,6.211538461538462,{"y":6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.6,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.21,"date":1730419200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":3.88,"date":1733011200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":4.7,"date":1735689600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":3.96,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.59,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.38,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.96,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.84,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.83,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.41,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.33,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.75,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >